Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis patients see Real-World quality of life gains with brodalumab

NCT ID NCT05132231

Symptom relief Sponsor: Bausch Health Americas, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Canadian study follows about 394 adults with plaque psoriasis who are starting brodalumab as part of their regular care. Over 12 months, researchers measure changes in skin-related quality of life, work productivity, and treatment satisfaction. The goal is to understand how this medication helps people manage symptoms and improve daily functioning in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

394 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants initiating brodalumab as part of routine clinical care and who meet all of the inclusion and none of the exclusion criteria are eligible to participate in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥ 18 years old at the time of verbal consent to participate in the study. 2. Initiating brodalumab as part of routine clinical care through the SILIQ (brodalumab) Patient Support Program (PSP) for the treatment of plaque psoriasis but has not yet received their first dose. Decision to treat with brodalumab must have been reached prior to and independently of recruitment in the study. 3. Must be able to read, understand, and communicate in English or French. 4. Willing and able to provide informed consent on an online platform using an Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved electronic Informed Consent Form (ICF) in English or French. Exclusion Criteria: 1. Not willing or able to complete ePROs (electronic Patient Reported Outcomes) on an online platform (using a computer or mobile device). 2. Participation in brodalumab phase IV study (NCT04149587). 3. Participation in an interventional clinical trial concurrently or within the last 30 days prior to providing verbal consent to participate in this study. 4. Patient with Crohn's disease or with clinically significant hypersensitivity to brodalumab or to any of the excipients or component of the container (contraindications as per the Product Monograph). 5. Presence of any other serious and/or uncontrolled medical condition that, in the opinion of the investigator, prohibits the patient from participating in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • CARE Site 03

    Saskatoon, Saskatchewan, S7T 0G3, Canada

  • CARE Site 04

    Montreal, Quebec, H2E 1V4, Canada

  • CARE Site 05

    Barrie, Ontario, L4M 7G1, Canada

  • CARE Site 06

    Greater Sudbury, Ontario, P3C 1XB, Canada

  • CARE Site 07

    Laval, Quebec, H7N 6L2, Canada

  • CARE Site 09

    London, Ontario, N6H 5L6, Canada

  • CARE Site 11

    Ajax, Ontario, L1S 7K8, Canada

  • CARE Site 12

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • CARE Site 13

    Richmond Hill, Ontario, L4C 9M7, Canada

  • CARE Site 14

    Hamilton, Ontario, L8N 1Y2, Canada

  • CARE Site 15

    Calgary, Alberta, T5J 3S9, Canada

  • CARE Site 16

    Toronto, Ontario, M5A 3R6, Canada

  • CARE Site 17

    Québec, Quebec, G3K 2P8, Canada

  • CARE Site 18

    Edmonton, Alberta, T5J 3S9, Canada

  • CARE Site 20

    Guelph, Ontario, N1L 0B7, Canada

  • CARE Site 21

    Edmonton, Alberta, T6W 0J5, Canada

  • CARE Site 22

    London, Ontario, N6A 5R9, Canada

  • CARE Site 23

    London, Ontario, N6A 2C2, Canada

  • CARE Site 24

    Hamilton, Ontario, L9B 1K5, Canada

  • CARE Site 26

    Calgary, Alberta, T2W 4X9, Canada

  • CARE Site 27

    Oshawa, Ontario, L1H 1B9, Canada

  • CARE Site 28

    Sherwood Park, Alberta, T8H 0P1, Canada

  • CARE Site 30

    Québec, Quebec, G1W 4R4, Canada

  • CARE Site 31

    Vancouver, British Columbia, V5Z 1M9, Canada

  • CARE Site 32

    Whitby, Ontario, L1N 8M7, Canada

  • CARE Site 33

    Markham, Ontario, L3P 1X3, Canada

  • CARE Site 35

    Saint Johns, Newfoundland and Labrador, A1E 1V4, Canada

  • CARE Site 36

    Winnipeg, Manitoba, R3C 0N2, Canada

  • CARE Site 37

    Edmonton, Alberta, T6X 0N9, Canada

  • CARE Site 38

    Drummondville, Quebec, J2B 5L4, Canada

  • CARE Site 39

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • CARE Site 40

    Westmount, Quebec, H3Z 2S6, Canada

  • CARE Site 41

    Edmonton, Alberta, T6G 1C3, Canada

  • CARE Site 42

    Calgary, Alberta, T2J 7E1, Canada

  • CARE Site 44

    Mississauga, Ontario, L4W 0C2, Canada

  • CARE Site 46

    Québec, Quebec, G1V T3, Canada

  • CARE Site 47

    Sherbrooke, Quebec, J1L 0H8, Canada

  • CARE Site 48

    North York, Ontario, M3B 0A7, Canada

  • CARE Site 49

    Toronto, Ontario, M2N 3A6, Canada

  • CARE Site 50

    Laval, Quebec, H7P K7, Canada

  • CARE Site 51

    Niagara Falls, Ontario, L2E 6A6, Canada

  • CARE Site 52

    Saint-Charles-Borromée, Quebec, J6E 4P6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.